GLG Network Survey: Generics Licensing

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 senior executives from pharma companies who market in-licensed products across the US and Europe (UK, France, Italy, Spain, and Germany).

What will you learn from this survey?

  • Respondents provided an overview of the generics B2B licensing market and business model.
  • The survey also investigated the typical selection criteria and competitive landscape amid Pharmathen, Synthon, Helm and Midas Pharma.
  • Lastly, the research analysed the growth drivers, opportunities and demand for the generics licensing industry.

Examples of findings:

  • In August 2024, close to two-in-five experts agree that around 2 to 3 years after the initial launch is the expected time until the project breaks even.
  • Four-in-ten experts report acquiring between 5 to 9 new in-licensed products each year.
  • 83% respondents believe that oncology will show significant growth in the next 5 years in the area of Generics.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Dr. Tassilo Krug von Nidda, former Global Head Portfolio at Sandoz.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • In the last 5 years, how has your reliance on B2B companies changed?
  • Approximately, how many new in-licensing products does your company acquire each year?
  • What are the reasons to choose an external source for your products?
  • What improvements would you like to see in the generics licensing services provided by your partners?
  • For which of the following reasons have you blacklisted companies?
  • According to current market, how likely are companies to expand their current generics portfolio in the next 2-3 years?
  • What areas of generics licensing do you think will experience significant growth in the next 5 years?
  • What features or services would be most valuable in a generics licensing partner?

Access

This survey is available to subscribers of the Healthcare (HC) sectors (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.